Elsevier

The Lancet

Volume 392, Issue 10149, 1–7 September 2018, Pages 716-717
The Lancet

Comment
Improving observational studies in the era of big data

https://doi.org/10.1016/S0140-6736(18)31619-2Get rights and content

References (7)

There are more references available in the full text version of this article.

Cited by (26)

  • Developing an ETL tool for converting the PCORnet CDM into the OMOP CDM to facilitate the COVID-19 data integration

    2022, Journal of Biomedical Informatics
    Citation Excerpt :

    Widespread enthusiasm for big data approaches has led to increasing popularity in conducting large observational studies in the assessment of new medical technologies in recent years [1].

  • Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data

    2021, Clinical Breast Cancer
    Citation Excerpt :

    Similarly, the integration of omics data with RWD requires a controlled approach for large-scale data analytics.24 RWE and integrated omics data have the power to impact patient care.3,25-27 Various studies show the additive value of molecular tumor profiling with RWD for clinically relevant breast cancer insights,8,28 but further advancements in the field require the integration of genetic and clinical data from a variety of institutions, along with omics-focused capabilities and data analytics.

  • Big data and precision oncology in healthcare

    2023, Big Data in Oncology: Impact, Challenges, and Risk Assessment
View all citing articles on Scopus
View full text